OGT-IN-2
CAS No. 442665-87-4
OGT-IN-2 ( —— )
Catalog No. M28850 CAS No. 442665-87-4
OGT-IN-2 is a potent O-GlcNAc transferase (OGT) inhibitor. OGT-IN-2 inhibits sOGT and ncOGT with IC50 values of 30 μM and 53 μM, respectively. OGT-IN-2 can be used for the research of articular diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 87 | Get Quote |
|
5MG | 151 | Get Quote |
|
10MG | 224 | Get Quote |
|
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameOGT-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionOGT-IN-2 is a potent O-GlcNAc transferase (OGT) inhibitor. OGT-IN-2 inhibits sOGT and ncOGT with IC50 values of 30 μM and 53 μM, respectively. OGT-IN-2 can be used for the research of articular diseases.
-
DescriptionOGT-IN-2 is a potent O-GlcNAc transferase (OGT) inhibitor. OGT-IN-2 inhibits sOGT and ncOGT with IC50 values of 30 μM and 53 μM, respectively. OGT-IN-2 can be used for the research of articular diseases.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor5-HT5A
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number442665-87-4
-
Formula Weight447.0
-
Molecular FormulaC23H27ClN2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(C(CC(N1CCC2(CC(C3)C4)CC4CC3C2)=O)SC1=Nc(cc1)ccc1Cl)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Aparicio-Nava L, Márquez-García LA, Meneses A. Effects of 5-HT5A receptor blockade on amnesia or forgetting. Behav Brain Res. 2019 Jan 14;357-358:98-103.
molnova catalog
related products
-
beta-Hydroxyacteosid...
beta-Hydroxyacteoside.
-
TOPS
TOPS is a Trinder's reagent and is widely used in diagnostic tests and biochemical tests.
-
Ensartinib hydrochlo...
Ensartinib dihydrochloride is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations.